Head-to-Head Comparison

TB-500 vs Ipamorelin: Which Has the Stronger Evidence Stack?

TB-500 (Thymosin Beta-4) is investigated for systemic wound healing, actin-driven cell migration, and tissue repair in animal models. Ipamorelin is a selective ghrelin-receptor GH secretagogue with a limited human pharmacodynamic anchor. TB-500 has zero published human efficacy RCTs, a narrow FDA orphan-drug designation for corneal wound healing without approval, and WADA S0 status. Ipamorelin has no human efficacy RCTs for the popular recovery, body-composition, sleep, or anti-aging uses, no FDA approval, and WADA S2 status.

This is an asymmetric comparison, not a contest between two proven therapies. TB-500 has a systemic tissue-repair and wound-healing story supported by animal and cellular evidence, but zero published human efficacy RCTs. Its FDA orphan-drug designation is narrow to corneal wound healing and is not approval for systemic injectable use. Ipamorelin has a limited human pharmacodynamic anchor for selective GH release (Raun 1998, PMID: 9783708), but no human efficacy RCTs for the recovery, body-composition, sleep, or anti-aging outcomes driving community interest. This page introduces no new citations; it maps the existing source deep-dives onto the TB-500 S0 versus Ipamorelin S2 distinction.

Verifiable Claims: Side-by-Side

Each row states a claim supported by a specific peer-reviewed citation where one exists, or by the established mechanism class already documented in the underlying deep-dives. PMIDs link to the corresponding PubMed record so the underlying study can be checked directly. Tier badges follow the evidence language used across PeptideDecoded content.

Claim TB-500 evidence Ipamorelin evidence
Mechanism / plausible target Strong (mechanistic)Thymosin Beta-4 binds monomeric G-actin and regulates actin organization, providing a biologically coherent basis for cell migration and tissue repair. PMID: 2642584 Strong (mechanistic)Selective ghrelin-receptor GHRP that acts at the somatotroph GHS-R1a receptor to release GH without the broader hormonal cross-reactivity associated with earlier GHRPs. PMID: 9783708
Wound healing / cell migration Animal onlyThymosin Beta-4 animal and cellular work supports accelerated wound closure, cell migration, and angiogenesis. These findings are preclinical and do not establish efficacy for systemic injectable TB-500 in humans. PMID: 10496477; PMID: 16841073 NoneIpamorelin's evidence base is a GH-secretagogue mechanism and pharmacodynamic signal, not wound-healing or cell-migration efficacy.
Systemic soft-tissue repair Animal onlyThe systemic repair narrative is supported by animal tissue-repair and cardiac-remodeling models, including the Thymosin Beta-4 cardiac-repair study. No published human efficacy RCT establishes tendon, ligament, or systemic recovery benefit. PMID: 14630500 Not establishedNo published evidence in the underlying Ipamorelin deep-dive establishes systemic wound healing, tendon repair, ligament repair, or soft-tissue recovery.
GH-axis pharmacodynamics Not establishedTB-500 is not a GH secretagogue and has no GH-pulse pharmacodynamic evidence in the source deep-dive set. Limited human pharmacodynamicRaun 1998 provides a narrow healthy-volunteer anchor for selective Ipamorelin-induced GH release. The broader GH-axis context in the source materials includes diagnostic-stimulation and GH-pulsatility literature (PMID: 8834260; PMID: 7527273), but those are not Ipamorelin efficacy trials. This is a pharmacodynamic endpoint, not evidence of recovery, body-composition, or anti-aging benefit. PMID: 9783708
Body composition / fat loss / muscle gain NoneZero published human efficacy RCTs for body-composition, fat-loss, or muscle-gain outcomes. NoneGH release is a surrogate, not an outcome. Zero published human efficacy RCTs support Ipamorelin for body composition, fat loss, or muscle gain.
Anti-aging / longevity outcomes NoneNo human efficacy RCT supports systemic TB-500 for anti-aging or longevity. Animal tissue-repair findings do not bridge that gap. NoneNo human efficacy RCT supports Ipamorelin for anti-aging or longevity. The GH-axis mechanism is not a validated longevity outcome.
Human randomized controlled trial (marketed efficacy uses) NoneZero published human efficacy RCTs for systemic wound healing, tendon or ligament repair, recovery, body composition, or anti-aging. NoneZero published human efficacy RCTs for body composition, recovery, sleep, or anti-aging. The human anchor is pharmacodynamic, not efficacy-based.
WADA status Prohibited (S0 — non-approved substances, at all times) Prohibited (S2 — GH-Releasing Factors / GHRPs, at all times)
FDA status Narrow FDA orphan-drug designation for corneal wound healing; designation is not approval and does not validate systemic injectable use. Not approved. Has never been FDA approved for any indication. No compounding monograph.

Citations reused from the TB-500 and Ipamorelin deep-dives only: TB-500 PMIDs 2642584, 10496477, 16841073, and 14630500; Ipamorelin/GH-axis context PMIDs 9783708, 8834260, and 7527273. No new citations introduced.

Dosing, Risk & Mechanism Matrix

These cards describe mechanism, regulatory context, and what is reported in the community. Any community dosing language is unvalidated; this page does not provide a dosing protocol.

TB-500

Thymosin Beta-4 · systemic tissue-repair and cell-migration biology
Mechanism Binds G-actin and influences actin organization, cell migration, angiogenesis, and wound-healing biology in preclinical models. PMID: 2642584
Route / dosing (community-reported) Systemic injectable use is discussed online, but protocols vary and are unvalidated. No published human trial establishes a safe or effective dose for tendon, ligament, recovery, or anti-aging use.
Risk profile Long-term safety is unknown. Product identity, purity, sterility, and actual exposure may be uncertain outside approved clinical research. Animal wound-healing data does not predict the human risk-benefit balance.
WADA status Prohibited under S0 at all times.
FDA status Not approved. The orphan-drug designation is narrow to corneal wound healing and is not approval for systemic TB-500.
Best-supported use case Preclinical research into tissue repair and cell migration. No validated human therapeutic indication.

Ipamorelin

Selective ghrelin-receptor GHRP · GHS-R1a GH-secretagogue mechanism
Mechanism Activates the GHS-R1a ghrelin receptor and promotes selective GH release. Raun 1998 is a limited human pharmacodynamic anchor, not an efficacy trial. PMID: 9783708
Route / dosing (community-reported) Subcutaneous schedules are commonly discussed in peptide communities, but the specific protocols are unvalidated. The source evidence does not support a dosing protocol for recovery, body composition, sleep, or anti-aging.
Risk profile Long-term safety and chronic-use outcomes are unknown. A selective GH-secretagogue signal does not establish a favorable clinical risk-benefit profile for marketed wellness uses.
WADA status Prohibited under S2 at all times.
FDA status Not approved for any indication. No compounding monograph.
Best-supported use case Narrow human pharmacodynamic research into selective GH release. No validated adult recovery, body-composition, sleep, or anti-aging indication.

Stacking Them

TB-500 + Ipamorelin · tissue-repair claim paired with GH-axis pharmacodynamics
Mechanism The compounds act through different biological stories: TB-500's actin/cell-migration pathway and Ipamorelin's GHS-R1a GH-secretagogue pathway. Different mechanisms are not evidence of a useful combination.
Route / dosing (community-reported) Community stacking discussions combine two unvalidated products. No source citation supports a combined protocol, schedule, dose, or duration.
Risk profile No published human safety or efficacy data on the combination. Stacking increases uncertainty and adds both S0 and S2 anti-doping exposure without closing either evidence gap.
WADA status TB-500 is S0 and Ipamorelin is S2; both are prohibited at all times.
FDA status Neither is FDA approved for the marketed uses. TB-500's orphan designation remains narrow and Ipamorelin has no approval.
Best-supported use case No supported use case in combination. Mechanistic speculation only, not a clinical-efficacy finding.

When to Choose Which

Three evidence-tier-grounded verdicts. Choosing one over the other does not establish human efficacy; it only clarifies which evidence gap a buyer is accepting.

Choose TB-500 if…

The question is about the actin / cell-migration research program, not a proven human repair therapy

TB-500 has a coherent systemic tissue-repair story and reproducible animal wound-healing biology, including G-actin binding, cell migration, and angiogenesis (PMID: 2642584; PMID: 10496477). Caveats: zero published human efficacy RCTs for systemic injectable use; the FDA orphan-drug designation is narrow to corneal wound healing and is not approval; WADA S0 prohibits it at all times. Animal evidence is not a human treatment result.

Choose Ipamorelin if…

The question is about a selective GH-secretagogue mechanism and the buyer accepts a limited pharmacodynamic anchor, not efficacy evidence

Ipamorelin has the clearer human pharmacodynamic anchor in this pair: Raun 1998 characterized selective GH release through the ghrelin receptor in healthy volunteers (PMID: 9783708). Caveats: zero published human efficacy RCTs for the popular recovery, body-composition, sleep, or anti-aging uses; community dosing is unvalidated; Ipamorelin is not FDA approved and is WADA S2-prohibited. A measured GH pulse is not a validated wellness outcome.

Consider neither as a stack if…

The goal is to turn two different mechanistic narratives into evidence for recovery, anti-aging, or body composition

Pairing TB-500's systemic animal tissue-repair story with Ipamorelin's GH-axis pharmacodynamics does not produce a published human efficacy finding. Caveats: no combined human safety or efficacy data; both products remain unapproved for the marketed uses; TB-500 remains S0 and Ipamorelin remains S2. The stack adds uncertainty and regulatory exposure without resolving either peptide's absence of human efficacy RCTs.

How to Read This Page

"Evidence tier" is the most important field in every claim above. Two peptides can appear in the same recovery conversation while the evidence behind their stories is fundamentally different.

Evidence tiers (high → none)

  • High (green) — human RCT data or a well-characterized mechanism.
  • Med (yellow) — moderate, replicated animal or preclinical evidence.
  • Low (red) — limited human pharmacodynamic or mechanistic evidence that does not establish efficacy.
  • None (gray) — no published human efficacy RCT data for the stated outcome.

What the gaps mean

  • Animal evidence is not human efficacy. TB-500's wound-healing and cell-migration evidence is preclinical; systemic injectable claims remain unproven in humans.
  • Pharmacodynamics are not outcomes. Ipamorelin's human GH-release anchor does not establish recovery, body-composition, sleep, or anti-aging benefit.
  • FDA designation is not approval. TB-500's corneal orphan-drug designation is narrow and does not authorize systemic use; Ipamorelin has no FDA approval.
  • WADA categories are different but equally consequential. TB-500 is S0 and Ipamorelin is S2; both are prohibited at all times.
  • Stacking does not close the evidence gap. Two unvalidated products and different mechanisms do not create a validated combination.

For deeper context on evaluating peptide claims, peer review, COI checks, red flags, and the pre-purchase checklist, see How to Verify Peptide Claims and the Editorial Standards page.

Read the Full Deep-Dives

This comparison is the synthesis. Open either underlying review to verify a claim, inspect the source trail, and read the full regulatory context.

TB-500
TB-500: What the Research Actually Says
G-actin binding, cell migration, wound-healing and tissue-repair animal evidence, the zero-human-efficacy-RCT gap, the narrow corneal orphan-drug designation, and WADA S0 status.
Read the full TB-500 deep-dive →
Ipamorelin
Ipamorelin: What the Research Actually Says
Selective GHS-R1a ghrelin-receptor pharmacology, the Raun 1998 human GH-pulse anchor, absent efficacy RCTs for marketed uses, no FDA approval, and WADA S2 status.
Read the full Ipamorelin deep-dive →
Research summary
TB-500 Research Summary
A focused overview of Thymosin Beta-4's mechanism, animal evidence, human evidence gap, FDA orphan-drug designation, and WADA position.
See the TB-500 research summary →
Catalog
All Peptide Deep-Dives
Browse the complete research library, including peptide deep-dives, comparisons, long-form guides, and regulatory context.
See all peptide deep-dives →
Research Literacy
Peptide Safety & Evidence Decoder Kit
A structured framework for evaluating peptide claims before you buy, follow a protocol, or trust a vendor.
Get the research-literacy kit →

When NOT to Use Either

Competitive athletes: TB-500 is prohibited at all times under WADA S0 and Ipamorelin is prohibited at all times under WADA S2. Different categories do not make either compound permissible for tested athletes.

Anyone seeking an FDA-approved therapy: neither peptide is approved for the marketed systemic recovery, body-composition, or anti-aging uses. TB-500's orphan-drug designation is narrow to corneal wound healing and is not approval; Ipamorelin has never been FDA approved.

Anyone needing proven human efficacy: TB-500 has animal wound-healing and tissue-repair evidence but zero published human efficacy RCTs. Ipamorelin has a limited human GH-release pharmacodynamic anchor but no human efficacy RCTs for the popular recovery, body-composition, sleep, or anti-aging uses. Community-reported outcomes and dosing are not clinical evidence.

Educational Only — Not Medical Advice

This comparison page is a research summary, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.

Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.